Roche’s Actemra shortage is another argument to suspend patents on Covid-19 drugs

Actemra, the anti-arthritis drug used to treat hospitalized Covid-19 patients, is in short supply.

The medication was approved for use on Covid-19 patients by the Food and Drug Administration in June, and the European Medicines Agency is currently evaluating its use. Demand for Actemra has gone up 400% above its pre-pandemic levels, according to Swiss pharmaceutical company Roche, which manufactures the drug through its subsidiary Genentech.

As cases of Covid-19 spike around the US and the world, the maker warned that the drug would be out of stock by the end of the week, and it will take two weeks to replenish supplies.

Read the rest of this story on Become a member to get unlimited access to Quartz’s journalism.

Originally published on Quartz : Original article

Leave a Reply

Your email address will not be published. Required fields are marked *